Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Serum insulin-like factor 3 levels are reduced in former androgen users suggesting impaired Leydig cell capacity

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Approach to the patient with glucocorticoid-induced adrenal insufficiency

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Quinine effects on gut and pancreatic hormones and antropyloroduodenal pressures in humans-role of delivery site and sex

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dynamic changes of reproductive hormones in male minipuberty: Temporal dissociation of Leydig- and Sertoli-cell activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Patients with cirrhosis have elevated bone turnover but normal hepatic production of osteoprotegerin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Lipoprotein(a) levels at birth and in early childhood: The COMPARE Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Dynamic Changes in LH/FSH Ratios in Infants with Normal Sex Development

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Dynamic changes of reproductive hormones in male minipuberty: Temporal dissociation of Leydig- and Sertoli-cell activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Oophorectomy and rate of dementia: a prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

CONTEXT: Illicit use of anabolic androgenic steroids (AAS) is frequently observed in men and is associated with subsequent testosterone deficiency although the long-term effect on gonadal function is still unclear. Serum insulin-like factor 3 (INSL3) has been suggested to be a superior biomarker of Leydig cell secretory capacity compared to testosterone.

OBJECTIVE: This study aimed to investigate serum INSL3 concentrations in AAS users.

METHODS: This community-based, cross-sectional study included men aged 18 to 50 years, involved in recreational strength training and allocated to 1 of 3 groups: never-AAS users as controls (n = 44), current (n = 46), or former AAS users (n = 42) with an average duration since AAS cessation of 32 (23 ; 45) months.

RESULTS: Serum INSL3 was lower in current AAS users and former AAS users than in controls, median (interquartile range), 0.04 µg/L (nondetectable [ND]-0.07 µg/L) and 0.39 µg/L (0.24-0.62 µg/L) vs 0.59 µg/L (0.45-0.72 µg/L), P less than .001. Former AAS users exhibited lower serum INSL3 levels than controls in a multivariable linear regression even after adjusting for serum total testosterone (TT) and other relevant confounders, (B) (95% CI), -0.16 µg/L (95% CI, -0.29 to -0.04 µg/L), P equal to .011. INSL3 and TT were not associated in the model, P equal to .821. Longer accumulated AAS duration (log2) was associated with lower serum INSL3 in former AAS users, (B) (95% CI), -0.08 (95% CI, -0.14 to -0.01), P equal to .022. Serum INSL3, but not inhibin B or testosterone, was associated with testicular size in a multivariate linear regression, (B) (95% CI); 4.7 (95% CI, 0.5 to 8.9), P equal to .030.

CONCLUSION: Serum INSL3 is reduced years following AAS cessation in men, independently of testosterone, suggesting persistently impaired Leydig cell capacity.

OriginalsprogEngelsk
TidsskriftThe Journal of clinical endocrinology and metabolism
Vol/bind106
Udgave nummer7
Sider (fra-til)e2664-e2672
ISSN0021-972X
DOI
StatusUdgivet - 16 jun. 2021

ID: 64128407